About the Authors
- Li Zhang
-
Affiliation State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
- Jin Wang
-
Affiliation Institute of Medical Science, Department of Pharmacology and Physiology, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China
- Aizhang Xu
-
Affiliation State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
- Conghao Zhong
-
Affiliation State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
- Wuguang Lu
-
Affiliation Laboratory of Cellular and Molecular Biology, Jiangsu Province Institute of Traditional Chinese Medicine, Nanjing, 210028, Jiangsu, China
- Li Deng
-
Affiliation Shanghai HyCharm Inc., 1 Fute Street East, Bldg. 458, Rm. 518, Shanghai 200131, China
- Rongxiu Li
-
* E-mail: rxli@sjtu.edu.cn
Affiliations State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China, Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education; Shanghai 200240, China
Competing Interests
I have read the journal’s policy and the author of this manuscript has the following competing interests: Li Deng is an employee of Shanghai HyCharm Inc. Shanghai HyCharm Inc has patented the methods of immunogen design (number WO2014/183649A1), and planned to develop an optimized version of TNF-α therapeutic vaccine. This does not alter the author’s adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: LZ AZX RXL. Formal analysis: JW. Funding acquisition: RXL. Investigation: LZ JW CHZ. Methodology: LZ JW AZX CHZ. Project administration: LZ. Resources: WGL. Supervision: RXL. Writing – original draft: LZ. Writing – review & editing: LZ LD RXL.